Deletion of angiotensin II type I receptor reduces hepatic steatosis

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1226-1235

  Nabeshima, Yoshitaka ^a   Tazuma, Susumu ^b   Kanno, Keishi ^b   Hyogo, Hideyuki ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Lipid metabolism; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Peroxisome proliferator activated receptor ; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CHOLINE; LONG CHAIN FATTY ACID; MESSENGER RNA; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; TELMISARTAN;

AMINO ACID DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DIET RESTRICTION; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION; WILD TYPE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BASE SEQUENCE; BENZIMIDAZOLES; BENZOATES; CELL LINE; DNA PRIMERS; FATTY LIVER; GENE SILENCING; HUMANS; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PPAR ALPHA; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 67349098446     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.018     Document Type: Article

References (46)

1. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
2. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 39 (2004) 188-196
3. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
4. Antonopoulos S., Mikros S., Mylonopoulou M., Kokkoris S., and Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 184 (2006) 233-234
5. Basaranoglu M., Acbay O., and Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with non-alcoholic steatohepatitis. J Hepatol 31 (1999) 384
6. Jin H., Yamamoto N., Uchida K., Terai S., and Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun 364 (2007) 801-807
7. Fujita K., Yoneda M., Wada K., Mawatari H., Takahashi H., Kirikoshi H., et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of non-alcoholic steatohepatitis in rats. Dig Dis Sci 52 (2007) 3455-3464
8. Bataller R., Gines P., Nicolas J.M., Gorbig M.N., Garcia-Ramallo E., Gasull X., et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118 (2000) 1149-1156
9. Kanno K., Tazuma S., Nishioka T., Hyogo H., and Chayama K. Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 50 (2005) 942-948
10. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
11. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
12. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., and Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38 (2001) 884-890
13. Sugimoto K., Kazdova L., Qi N.R., Hyakukoku M., Kren V., Simakova M., et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens 26 (2008) 1209-1215
14. Ibanez P., Solis N., Pizarro M., Aguayo G., Duarte I., Miquel J.F., et al. Effect of losartan on early liver fibrosis development in a rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22 (2007) 846-851
15. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
16. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
17. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat non-alcoholic steatohepatitis. Hepatology 45 (2007) 1375-1381
18. Burson J.M., Aguilera G., Gross K.W., and Sigmund C.D. Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 267 (1994) E260-E267
19. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270 (1995) 18719-18722
20. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
21. Malhi H., Bronk S.F., Werneburg N.W., and Gores G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 281 (2006) 12093-12101
22. Greenspan P., and Fowler S.D. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 26 (1985) 781-789
23. Gomez-Lechon M.J., Donato M.T., Martinez-Romero A., Jimenez N., Castell J.V., and O'Connor J.E. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165 (2007) 106-116
24. Tomita K., Oike Y., Teratani T., Taguchi T., Noguchi M., Suzuki T., et al. Hepatic AdipoR2 signaling plays a protective role against progression of non-alcoholic steatohepatitis in mice. Hepatology 48 (2008) 458-473
25. Igolnikov A.C., and Green R.M. Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. J Hepatol 44 (2006) 586-592
26. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits?. Gastroenterology 114 (1998) 842-845
27. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., and Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123 (2002) 1667-1676
28. Ran J., Hirano T., and Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens 23 (2005) 1525-1530
29. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 1003-1009
30. Kurita S., Takamura T., Ota T., Matsuzawa-Nagata N., Kita Y., Uno M., et al. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Eur J Pharmacol 588 (2008) 316-324
31. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001) 745-750
32. Kanno K., Tazuma S., and Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun 308 (2003) 177-183
33. Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112 (2003) 1383-1394
34. Campbell D.J., Alexiou T., Xiao H.D., Fuchs S., McKinley M.J., Corvol P., et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 43 (2004) 854-859
35. Jayasooriya A.P., Mathai M.L., Walker L.L., Begg D.P., Denton D.A., Cameron-Smith D., et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 105 (2008) 6531-6536
36. Clemenz M., Frost N., Schupp M., Caron S., Foryst-Ludwig A., Bohm C., et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 57 (2008) 1405-1413
37. Mandard S., Müller M., and Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61 (2004) 393-416
38. Luci S., Giemsa B., Kluge H., and Eder K. Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. Am J Physiol Regul Integr Comp Physiol 293 (2007) R70-R77
39. Rinella M.E., and Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 (2004) 47-51
40. Vetelainen R., van Vliet A., and van Gulik T.M. Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. J Gastroenterol Hepatol 22 (2007) 1526-1533
41. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002) 367-372
42. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
43. Collins S., Martin T.L., Surwit R.S., and Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81 (2004) 243-248
44. Deng Q.G., She H., Cheng J.H., French S.W., Koop D.R., Xiong S., et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42 (2005) 905-914
45. Koteish A., and Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 679-690
46. Gonzalez F.J., Peters J.M., and Cattley R.C. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst 90 (1998) 1702-1709